Autoimmune polyendocrinopathy candidiasis ectodermal dystrophy and other primary immunodeficiency diseases help to resolve the nature of protective immunity against chronic mucocutaneous candidiasis.
OBJECTIVE
This review summarizes and discusses the most recent and important publications describing Mendelian diseases associated with susceptibility to chronic mucocutaneous candidiasis (CMC) as a means of gaining insight into the pathogenesis of this immunodeficiency.


RESULTS
Impairment to T helper 17 (Th17) cell-associated signalling pathways are common in immunodeficiency syndromes associated with CMC infections. Mutations in CARD9, STAT3, IL17RA, IL17F, STAT1, and IL12RB and polymorphisms in Dectin 1 and interleukin-22 (IL-22) encoding genes have been shown to impair the development or function of Th17 cells and are associated with susceptibility to candidiasis. Studies on autoimmune polyendocrinopathy candidiasis ectodermal dystrophy have revealed autoimmunity to Th17 cytokines and cells as the basis for CMC. IL-17A, IL-17F, and IL-22 induce production of antimicrobial peptides and chemoattractants that recruit neutrophils in response to invading fungi. Th17 cell-associated cytokines may play a role in shaping the host's microbiome (that competes with C. albicans) preventing overgrowth of this pathogen. Recent evidence also suggests that IL-22 together with IL-17F might be the most important Th17 cytokine in protection against Candida.


CONCLUSIONS
Dissection of critical molecular and immunological mechanisms will allow the development of new treatments for primary and secondary immunodeficiency disorders resulting in chronic Candida infections.
Molecular Pathology, Institute of Biomedicine and Translational Medicine, University of Tartu, Tartu, Estonia.
Kai
K
Kisand
Pärt
P
Peterson
D057134:Antibodies, Neutralizing / Q000276:immunology*; D000935:Antifungal Agents / Q000276:immunology; D015551:Autoimmunity; D002178:Candidiasis, Chronic Mucocutaneous / Q000235:genetics / Q000276:immunology* / Q000628:therapy; D002630:Chemotactic Factors / Q000235:genetics / Q000276:immunology; D004198:Disease Susceptibility; D005260:Female; D006801:Humans; D007113:Immunity, Innate / Q000235:genetics / Q000276:immunology*; D020381:Interleukin-17 / Q000276:immunology; D007378:Interleukins / Q000276:immunology; D008297:Male; D009154:Mutation; D016884:Polyendocrinopathies, Autoimmune / Q000235:genetics / Q000276:immunology* / Q000628:therapy; D020641:Polymorphism, Single Nucleotide; D015398:Signal Transduction / Q000276:immunology; D058504:Th17 Cells / Q000276:immunology*; D055815:Young Adult; D000097043:Interleukin-22
D057134:Antibodies, Neutralizing; D000935:Antifungal Agents; D002630:Chemotactic Factors; D020381:Interleukin-17; D007378:Interleukins; D000097043:Interleukin-22